• Resiquimod (R-848): Enhancing Tumor Ablation with Immune Mod

  2026-08-03

  Resiquimod (R-848) unlocks new paradigms in cancer immunotherapy by integrating immune activation with thermal ablation workflows. This article reveals how dual-responsive hydrogel systems leverage R-848’s TLR7/8 agonism for safer, more effective tumor eradication, plus protocols, troubleshooting, and real-world research insights.

• Nigericin: Precision pH Modulation and Mitochondrial Ion Tra

  2026-08-02

  Explore Nigericin's role as a potassium/hydrogen ion carrier in advanced oncology and antimicrobial research. This article offers a unique, in-depth analysis of Nigericin’s mechanistic impact on intracellular pH and mitochondrial ion transport, distinguishing its applications from recent metabolic intervention strategies.

• Ferroptosis-Induced Macrophage Reprogramming Boosts Immunoth

  2026-08-01

  This study uncovers how ferroptosis in tumor cells enhances antigen presentation by tumor-associated macrophages, ultimately improving immune checkpoint blockade efficacy. By delineating the ATRA–RARα–CD38–TFEB axis, it provides mechanistic insight and translational strategies for leveraging ferroptosis in cancer immunotherapy.

• Biotin-XX Tyramide Reagent: Benchmarking Cell Surface Labeli

  2026-07-31

  Biotin-XX Tyramide Reagent delivers robust, membrane-impermeant proximity labeling for high-sensitivity cell surface protein detection. Its long polar linker and HRP-catalyzed deposition enable unrivaled selectivity and amplification for immunohistochemistry and in situ hybridization workflows.

• Tubastatin A (SKU A4101): Precision HDAC6 Inhibition for Ass

  2026-07-31

  This article provides a scenario-driven, data-backed guide to using Tubastatin A (SKU A4101) for robust cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed evidence and practical lab concerns, we illustrate how this HDAC6 inhibitor enhances reproducibility and mechanistic clarity for biomedical researchers.

• Tioconazole as a Precision Tool for Mechanistic Fungal Resea

  2026-07-30

  Explore how Tioconazole, a potent antifungal medication, enables advanced mechanistic studies in fungal cell biology and drug development. This article uniquely connects Tioconazole’s molecular action to current innovations in metabolic-genomic research.

• BMX-IN-1: Decoding BMX Kinase Inhibition for Host-Pathogen a

  2026-07-30

  Explore how BMX-IN-1, a highly selective BMX kinase inhibitor, advances both infectious disease and cancer research by targeting key signaling pathways. This article uniquely details mechanistic insights, experimental protocols, and cross-domain applications, drawing on recent landmark studies.

• Perineuronal Net Degradation Drives Social Memory Loss in AD

  2026-07-29

  This study demonstrates that disruption of perineuronal nets (PNNs) in the hippocampal CA2 region underlies social cognition memory deficits in Alzheimer’s disease (AD) models. The findings highlight matrix metalloproteinase (MMP)-mediated PNN degradation as a driver of pathology, and suggest that MMP inhibition can preserve social memory, offering a new mechanistic target in AD research.

• Butylhydroxyanisole (BHA): Reliable Antioxidant for Cell Ass

  2026-07-29

  Explore how Butylhydroxyanisole (BHA, SKU C6525) addresses oxidative stress assay challenges with validated antioxidant performance. This article guides biomedical researchers through scenario-driven solutions for reproducibility and data integrity using BHA in cell viability and ROS detection workflows.

• Physicochemical Properties Drive Nanoparticle Uptake in Corn

  2026-07-28

  This study systematically dissects how nanoparticle size and surface chemistry govern the cellular uptake mechanisms in human corneal epithelial cells. The findings establish energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated pathways, as dominant, informing rational design of ocular drug delivery systems.

• Tomivosertib: Applied MNK1 Inhibitor Workflows & Protocols

  2026-07-28

  Tomivosertib offers researchers a potent, selective MNK1 inhibitor for dissecting translational control in cancer, neuronal, and metabolic models. This guide distills evidence-backed workflows, advanced troubleshooting, and practical insights, enabling precise modulation of the MNK-eIF4E pathway in cutting-edge research.

• SB743921: Precision Kinesin Spindle Protein Inhibitor Workfl

  2026-07-27

  SB743921 is a nanomolar-potency kinesin spindle protein inhibitor that empowers cancer researchers to induce mitotic arrest and apoptosis with remarkable selectivity. This guide delivers actionable protocols, troubleshooting strategies, and advanced workflow enhancements for reproducible results in both in vitro and tumor xenograft models.

• Applied Use-Cases of Verapamil ((±)-Verapamil) in Hypoxia Mo

  2026-07-27

  Verapamil ((±)-Verapamil) enables precise, reproducible modulation of hypoxia-driven inflammation in urothelial cell models—extending its utility well beyond classic cardiovascular research. Recent studies demonstrate its value in dissecting the ROS/TXNIP/NLRP3 axis and overcoming protocol challenges in BOO-relevant inflammation assays.

• Pexidartinib (PLX3397): Advancing Macrophage Modulation in O

  2026-07-26

  This thought-leadership article explores how Pexidartinib (PLX3397), a selective CSF1R inhibitor, empowers translational researchers to strategically target tumor-associated macrophages (TAMs) and modulate the tumor microenvironment. We integrate mechanistic insights, validate experimental approaches, and provide strategic guidance for optimizing anti-tumor research workflows, all while contextualizing recent breakthroughs in TAM-targeted therapies. Drawing from recent studies—including landmark findings on SPP1 inhibition and macrophage reprogramming—we outline the evolving landscape of macrophage-directed cancer therapies and offer actionable recommendations for leveraging Pexidartinib (PLX3397) in translational oncology.

• Epalrestat Activates KEAP1/Nrf2 Pathway for Parkinson’s Neur

  2026-07-25

  Jia et al. (2025) provide the first direct evidence that Epalrestat, a clinically used aldose reductase inhibitor, confers neuroprotection in Parkinson’s disease models by activating the KEAP1/Nrf2 pathway. This mechanistic insight advances our understanding of oxidative stress modulation in neurodegenerative research and supports the repositioning of Epalrestat for CNS disease models.

7616 records 4/508 page Previous Next 12345 下5页 Last page